Symptoms Over Syndromes: Why the Pieces Matter More Than the Label

Starting from experience

No one experiences "major depressive disorder." People experience not being able to enjoy anything, not being able to start anything, exhaustion that sleep does not fix, lying awake at 3 a.m., a short fuse, a clouded mind, a body that wants too much food or none. They experience symptoms. The diagnostic label is a summary imposed afterward — and, as the diagnostics capstone argued at length, often a biologically loose one. This capstone takes the symptoms documented in this series — anhedonia, motivation loss, fatigue, sleeplessness, anger and irritability, brain fog, and appetite change — and argues that they are not a scattered list but a structured map: they cut across diagnoses, they cluster by shared brain mechanisms, and those mechanisms are the very ones this whole library has been tracing.

Why symptoms, not just syndromes

The single most important idea is that these symptoms are transdiagnostic. Anhedonia appears in depression, schizophrenia, Parkinson's, and addiction. Fatigue and brain fog span depression, long COVID, multiple sclerosis, and cancer treatment. Irritability runs through depression, bipolar disorder, PTSD, dementia, and childhood mood dysregulation. The same symptom appears under many diagnostic labels, and — just as tellingly — the same label contains wildly different symptom profiles: two people with the identical diagnosis of depression may share almost no symptoms, one losing sleep and appetite and the other oversleeping and overeating.

This is the same heterogeneity that frustrates the search for diagnostic biomarkers, viewed from the other side. It is why a purely category-based approach to treatment is so blunt, and it is the rationale behind dimensional and symptom-focused frameworks (such as the Research Domain Criteria) that study the building blocks — reward, threat, arousal, cognition — across diagnoses rather than within them. The practical payoff is that a symptom, tied to a mechanism, is often a more tractable target than a syndrome.

The symptoms cluster — they are not independent

These symptoms travel together, and not by coincidence. They fall into recognizable clusters defined by shared circuitry.

The largest is the reward–drive–energy cluster: anhedonia, low motivation, and fatigue, with the hedonic side of appetite and the effortful side of cognition pulled in alongside. These are not separate problems that happen to co-occur; they are different surface readings of one underlying machine — the brain's system for calculating whether a reward is worth the effort. When that system is down-regulated, the person cannot want (anhedonia), cannot start (low motivation), feels the cost of any action as exhaustion (fatigue), finds thinking effortful (brain fog), and may lose or seek food through the reward pathway (appetite).

A second cluster centers on arousal and its dysregulation: insomnia is arousal set too high at night, irritability is the threat system too easily tripped, and both are worsened by the stress hormones that also disrupt attention and appetite. Appetite, finally, serves as a bidirectional dial — pointing toward a stress-driven profile when it falls and an inflammatory-metabolic profile when it rises.

Recognizing the clusters changes clinical thinking. A patient who is anhedonic, unmotivated, and exhausted does not have three problems requiring three solutions; they have one circuit in trouble, which is why the same interventions — dopamine-oriented strategies, behavioral activation, exercise, attention to inflammation — recur across all three.

The shared mechanisms are the library's convergence themes

Seen from the symptom side, the mechanisms are the same convergence points this library has mapped from the etiology side. Four recur:

Dopamine, reward, and effort. The reward-and-effort circuitry running through the ventral striatum and anterior cingulate is the engine of anhedonia, motivation, fatigue, and hedonic appetite — the symptomatic face of the dopaminergic account.

Inflammation and sickness behavior. This is the most unifying mechanism of all. The evolutionarily ancient response to immune activation — fatigue, withdrawal, anhedonia, cognitive slowing, altered appetite — is itself a coordinated symptom cluster, hardwired to conserve energy during illness. When that program is switched on inappropriately, as in the inflammatory and immunometabolic subtypes, it produces much of the reward–drive–energy cluster at once.

Arousal and the stress axis. HPA-axis and sympathetic overactivity drive the hyperarousal of insomnia, the threat-reactivity of irritability, and the appetite suppression of melancholic states — the symptomatic expression of chronic stress and allostatic load, the library's upstream convergence node.

Plasticity and the prefrontal–limbic balance. Cognitive symptoms trace to the prefrontal cortex and hippocampus and to the neuroplasticity/BDNF signaling that this library treats as its downstream hub, while anger reflects the amygdala–prefrontal balance that stress and trauma degrade.

In other words, the symptoms are the surface readouts of the same causal web the depression etiology capstone bracketed between an upstream stress node and a downstream plasticity node. The symptoms are where that web becomes something a person can feel.

What this means for treatment

If symptoms dissociate from diagnoses, cluster by mechanism, and respond to different things, then the rational approach is to identify and target the specific symptoms and their mechanisms rather than treating a diagnostic label monolithically. This is the logic of measurement-based care, and the documents in this series are full of its consequences: SSRIs are a poor fit for anhedonia, which calls for dopamine-oriented and behavioral strategies; insomnia responds best to a behavioral therapy (CBT-I), not a sedative; motivation deficits may improve most when an offending medication is removed; cognitive symptoms call for specific pro-cognitive agents and rehabilitation; irritability demands first that its context — especially a possible mixed state — be identified.

Two further clinical truths run through the series. First, residual symptoms predict relapse: fatigue, cognitive symptoms, anhedonia, and insomnia that linger after "successful" treatment are not cosmetic leftovers but markers of incomplete recovery and risk, which is why treating to remission across symptoms matters. Second, the symptoms that most determine whether someone can live their life — motivation, cognition, fatigue — are often the quietest and the least well served by standard treatment, while the noisier symptoms get the attention.

Honest limits

Several cautions temper this picture. Symptoms are subjective and overlapping, and the boundaries between anhedonia, low motivation, fatigue, and brain fog genuinely blur — patients and clinicians cannot always tell them apart, and they are hard to measure cleanly. Subjective report and objective testing frequently dissociate, most visibly in cognition, and both deserve respect. The same symptom can have many causes, so naming it is only the start; the discipline is the differential. The mechanisms remain incompletely understood, and truly symptom-specific, mechanism-targeted treatment is still more aspiration than reality. And symptoms are not only circuit readouts: they are also meaningful human experiences embedded in a life, and — as the etiology capstone's levels-of-explanation argument holds — a valid biological account of fatigue or irritability does not displace the personal and situational levels at which those experiences are equally real.

Bottom line

Symptoms are the transdiagnostic, mechanism-linked surface of the same causal web this library has mapped from below. They are not an arbitrary list but a structured map: anhedonia, low motivation, fatigue, and the effortful edges of cognition and appetite cluster around the dopamine reward-and-effort engine and the inflammatory sickness-behavior program; insomnia and irritability cluster around arousal and the stress axis; cognition and anger reflect the plasticity and prefrontal–limbic systems; and appetite's direction reads out which subtype is in play. Because these symptoms cross diagnoses and respond to different things, the future of good care is symptom- and mechanism-targeted and measurement-based rather than label-driven — pursued with humility about how subjective, overlapping, and incompletely understood these experiences remain, and with respect for the fact that behind every mapped circuit is a person who simply cannot enjoy, start, rest, focus, or settle, and wants to be able to again.

Selected references

1. Insel T, et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010.
2. Fried EI, Nesse RM. Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR*D study. J Affect Disord. 2015.
3. Dantzer R, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008.
4. Husain M, Roiser JP. Neuroscience of apathy and anhedonia: a transdiagnostic approach. Nat Rev Neurosci. 2018.
5. Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev. 2011.
6. Salamone JD, Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron. 2012.
7. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016.
8. Pizzagalli DA. Depression, stress, and anhedonia: toward a synthesis and integrated model. Annu Rev Clin Psychol. 2014.
9. McIntyre RS, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013.
10. Riemann D, et al. The hyperarousal model of insomnia. Sleep Med Rev. 2010.
11. Leibenluft E. Irritability in children: what we know and what we need to learn. World Psychiatry. 2017.
12. Simmons WK, et al. Appetite changes reveal depression subgroups with distinct endocrine, metabolic, and immune states. Mol Psychiatry. 2020.
13. Milaneschi Y, et al. Depression heterogeneity and its biological underpinnings: immunometabolic depression. Biol Psychiatry. 2020.
14. Kotov R, et al. The Hierarchical Taxonomy of Psychopathology (HiTOP). J Abnorm Psychol. 2017.
15. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission. Psychol Med. 2011.
16. Trivedi MH, et al. Measurement-based care for refractory depression. Am J Psychiatry / J Clin Psychiatry (measurement-based care literature).